Inhibitory Effect of Hydroxysafflor Yellow B on the Proliferation of Human Breast Cancer MCF-7 Cells

2019 ◽  
Vol 14 (2) ◽  
pp. 187-197 ◽  
Author(s):  
Chuanjun Qu ◽  
Weiwei Zhu ◽  
Kaijie Dong ◽  
Zhaohai Pan ◽  
Ying Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Flow Cytometry ◽  
Cell Apoptosis ◽  
Human Breast Cancer ◽  
S Phase ◽  
Dependent Manner ◽  
Human Breast ◽  
Protein Levels ◽  
Mcf 7

Background:A recent patent has been issued for hydroxysafflor yellow A (HSYA) as a drug to prevent blood circulation disorders. Hydroxysafflor yellow B (HSYB), an isomer of HSYA with antioxidative effects, has been isolated from the florets of Carthamus tinctorius. The effects of HSYB on the proliferation of cancer cells and its mechanism of action have not been investigated.Objective:The aims of this study were to investigate the anti-cancer effects and the molecular mechanism of HSYB for breast cancer MCF-7 cells.Methods:MTT assays and colony formation assays were used to assess the survival and proliferation of MCF-7 cells, respectively. Hoechst 33258 and flow cytometry were used to measure cell apoptosis and flow cytometry to determine effects on the cell cycle. Western blots were used to measure protein levels.Results:Treatment with HSYB reduced survival and proliferation of human breast cancer MCF-7 cells in a dose-dependent manner. Furthermore, HSYB arrested the MCF-7 cell cycle at the S phase and downregulated cyclin D1, cyclin E, and CDK2. Compared with a control group, HSYB suppressed the protein levels of p-PI3K, PI3K, AKT, and p-AKT in MCF-7 cells. In addition, HSYB decreased the levels of Bcl- 2, increased the levels of Bax, cleaved caspase-3 and caspase-9, and subsequently induced MCF-7 cell apoptosis.Conclusion:These data demonstrate that HSYB arrests the MCF-7 cell cycle at the S phase and induces cell apoptosis. Patent US20170246228 indicates that HSYB can be potentially used for the prevention and treatment of human breast cancer.

Effect of extracts from Phyllanthus watsonii Airy Shaw on cell apoptosis in cultured human breast cancer MCF-7 cells

2013 ◽  
Vol 65 (3) ◽  
pp. 341-349 ◽  
Author(s):  
Sujatha Ramasamy ◽  
Norhanom Abdul Wahab ◽  
Nurhayati Zainal Abidin ◽  
Sugumaran Manickam
Keyword(s):  
Breast Cancer ◽  
Cell Apoptosis ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Mcf 7

scholarly journals Cytotoxic activity of crude saponins from Gaultheria trichophylla against human breast cancer cells MCF-7 and MDA-MB-468

2015 ◽  
Vol 10 (2) ◽  
pp. 443
Author(s):  
Fiaz Alam ◽  
Qazi Najam us Saqib ◽  
Abdul Waheed
Keyword(s):  
Breast Cancer ◽  
Cell Viability ◽  
Crude Extract ◽  
Human Breast Cancer ◽  
Neutral Red ◽  
Breast Cancer Cell Lines ◽  
Dependent Manner ◽  
Human Breast ◽  
Uptake Assay ◽  
Mcf 7

<p>This study was conducted to evaluate <em>Gaultheria trichophylla</em> crude extract and respective saponins fraction against human breast cancer cell lines. In MTT assay, cell viability was inhibited by <em>G. trichophylla</em> crude extract (500 µg/mL) and saponins (200 µg/mL) in a dose dependent manner with maximum inhibition of (82% and 85%) and (71% and 42%) against MCF-7 and MDA MB-468, respectively. In neutral red uptake assay, the cell viability was inhibited by crude extract and saponins (100 µg/mL) in a similar manner with maximum inhibitions of (96% and 93%) and (87% and 61%) against MCF-7 and MDA MB-468, respectively, with respect to 91% and 93% inhibition by actinomycin-D (4 µM). The DAPI (4',6-diamidino-2-phenylindole) (10 µg/mL) staining of MCF-7 cells treated with crude saponins showed shrunken nuclei with apparent nuclear fragmentation indicating apoptosis and in contrast, MDA MB-468 showed necrosis mode of cell death. The study exhibited that the <em>G. trichophylla</em> provides new evidences to further explore this plant for the novel targets in anticancer drug development.</p>

scholarly journals Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro

1993 ◽  
Vol 67 (2) ◽  
pp. 232-236 ◽  
Author(s):  
JA Foekens ◽  
AM Sieuwerts ◽  
EMJ Stuurman-Smeets ◽  
HA Peters ◽  
JGM Klijn
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Cell Cycle Kinetics ◽  
Kinetics Of ◽  
Mcf 7

scholarly journals Formulation and Development of Transferrin Targeted Solid Lipid Nanoparticles for Breast Cancer Therapy

2020 ◽  
Vol 11 ◽  
Author(s):  
Geeta S. Bhagwat ◽  
Rajani B. Athawale ◽  
Rajeev P. Gude ◽  
Shadab Md ◽  
Nabil A. Alhakamy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Solid Lipid Nanoparticles ◽  
Human Breast Cancer ◽  
Lipid Nanoparticles ◽  
Dependent Manner ◽  
Human Breast ◽  
Solid Lipid ◽  
Receptor Modulation ◽  
Tamoxifen Citrate ◽  
Mcf 7

Breast cancer is conventionally treated by surgery, chemotherapy and radiation therapy followed by post operational hormonal therapy. Tamoxifen citrate is a best option to treat breast cancer because its selective estrogen receptor modulation activity. Owing to its antiestrogenic action on breast as well as uterine cells, Tamoxifen citrate shows uterine toxicity. The dose 20 mg per day of Tamoxifen citrate required to show therapeutic effect causes side effects and toxicity to vital organs such as liver, kidney and uterus. In the present study, transferrin-conjugated solid lipid nanoparticles (SLNs) were successfully prepared to enhance the active targeting of tamoxifen citrate in breast cancer. Developed formulations were evaluated for particle size, surface charge, surface morphology and in vitro dissolution studies. Developed formulations exhibited more cytotoxicity as compared to pure Tamoxifen citrate solution in time as well as concentration dependent manner on human breast cancer MCF-7 cells. Further, cell uptake and flow cytometry studies confirmed the qualitative uptake of developed D-SLN and SMD-SLN by human breast cancer MCF-7 cells. Overall, proposed study highlights that transferrin engineered nanocarriers could enhance the therapeutic response of nanomedicines for breast cancer treatment.

Ganoderma lucidum Extract Induces G1 Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells

2012 ◽  
Vol 40 (03) ◽  
pp. 631-642 ◽  
Author(s):  
Guosheng Wu ◽  
Zhengming Qian ◽  
Jiajie Guo ◽  
Dejun Hu ◽  
Jiaolin Bao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cancer Cells ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Cycle Arrest ◽  
G1 Cell Cycle Arrest ◽  
Mcf 7

Ganoderma lucidum (Fr.) Karst is a traditional Chinese herb that has been widely used for centuries to treat various diseases including cancer. Herein, an ethanol-soluble and acidic component (ESAC), which mainly contains triterpenes, was prepared from G. lucidum and its anti-tumor effects in vitro were tested on human breast cancer cells. Our results showed that ESAC reduced the cell viability of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with IC50 of about 100 μg/mL and 60 μg/mL, respectively. DNA damage was detected by Comet assay and the increased expression of γ-H2AX after ESAC treatment was determined in MCF-7 cells. Moreover, ESAC effectively mediated G1 cell cycle arrest in both concentration- and time-dependent manners and induced apoptosis as determined by Hoechst staining, DNA fragment assay and Western blot analysis in MCF-7 cells. In conclusion, ESAC exerts anti-proliferation effects by inducing DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells.

Sign in / Sign up

Export Citation Format

Share Document